Learn more: To view or add a comment, sign in Big news in the world of type 1 diabetes care Sanofi's Teplizumab (Tzield) is now approved in the U.S
"Rapid fat loss in patients taking semaglutide or similar GLP-1 receptor agonists can make wrinkles more prominent and cause skin sagging in areas like the temples, cheeks, tear troughs, jawline, marionette lines and nasolabial folds, disrupting facial balance
Overcoming weight management hurdles is challenging enough, and many people using GLP-1s value the possibility of sustaining their progress without dependency on medication
This is kinda wild
But while the research is a step in the right direction when it comes to diagnosing depression using blood, McEwen said: "It is likely that other biomarkers will be needed to further identify, or narrow down, to create a more specific depression subtype